Moroctocog alfa is a recombinant Factor VIII used to treat hemophilia A to control bleeding. Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function.
- Mechanism
- Curator reviewed
Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia). As factor VIII is the specific clotting factor deficient in patients with hemophilia A, replacement of clotting factor with Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is the cornerstone of the prevention and treatment of bleeding for this disorder.
- Primary indication
- Moroctocog alfa is indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of...Curator reviewed · 3 structured indications
- Formula / weight
- 173000.0 Da (glycosylated)
- First approval
- Canada, 2003 · United States, 2008 · European Union, 2016
- Also known as
- Antihemophilic factor (recombinant, B-domain deleted), plasma/albumin free · Antihemophilic factor recombinant plasma/albumin free · Antihemphilic factor, recombinant human B-domain deleted · B-domain deleted recombinant factor VIII · BDDrFVIII
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Moroctocog alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account